Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. (10th August 2021)

• Record Type: Journal Article
• Authors: Schultz-Cherry, Stacey; McGargill, Maureen A; Thomas, Paul G; Estepp, Jeremie H; Gaur, Aditya H; Allen, E Kaitlynn; Allison, Kim J; Tang, Li; Webby, Richard J; Cherry, Sean D; Lin, Chun-Yang; Fabrizio, Thomas; Tuomanen, Elaine I; Wolf, Joshua
• Is Part Of: Open forum infectious diseases. Volume 8:Number 9(2021)
• Publication Date: 2021-08-10
• Subjects: antibody -- bamlanivimab -- COVID-19 -- SARS-CoV-2 -- vaccine failure; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab420
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board–approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration. : The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995 .